CTRI/2023/12/060971Not yet recruitingPhase 3
Pharmaceutico Analytical study of modified dosage forms (Lepa guti) of Varun Twak Lepa and Krushnatiladi Lepa and their comparative clinical evaluation in Vyanga (Melasma) – A Randomized Controlled Trial - NI
Dr Pratiksha Mahure0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients willing for participation in the study & ready to give written informed consent.
- •Patients between the age group of 18-50 years will be selected for study.
- •Patients irrespective of sex, caste, religion, occupation, economic status and will be selected for the study.
- •Chronicity less than 5 years will be selected.
- •Patients with clinical features of Vyanga as per Ayurvedic classics will be included.[2]
- •Pregnancy & Lactating woman having Vyanga.
- •Von Luschan’s Color Scale ranging from 17 to 30.
Exclusion Criteria
- •Patients with past and present history of any skin diseases e.g. Psoriasis, Dermatitis, Vitiligo etc.
- •Person suffering from any bacterial or fungal infection, viral infection with antibiotics, antifungal and antiviral drugs.
- •Patients with rashes over face and open wound at face.
- •Patients with history of hyperpigmentation since birth like Neavus of Ota, tumours like malignant melanoma, drug induced Pigmentation changes etc
- •Patient suffering with systemic disorders like renal failure, hepatic disorder.
- •Patients with known case of endocrinal disorders like Addison’s disease, Cushing’s disease. Acne, etc.
- •Person with big or dark scars on face.
Investigators
Similar Trials
Not yet recruiting
Phase 2
Management of Mukhadushika (Acne vulgaris) with ayurvedic medicatioCTRI/2023/11/060217Dr Neha Lidbe
Completed
Not Applicable
Study on pharmacokinetics and dosage adaptation of meropenem in pediatric patients receiving continuous hemodiafiltratioInfectious diseasesJPRN-UMIN000014904Department of clinical pharmacology and genetics, school of pharmaceutical science, university of Shizuoka graduate school70
Active, not recruiting
Phase 1
A research study to learn about the effects of IMB-1018972, to try and help your heart cell use energy more efficiently, to find the best dose, and to see how safe it is. This is for patients who may be at risk for a heart condition known as diabetic cardiomyopathy (DbCM) as a complication of a type 2 diabetes mellitus (T2DM).EUCTR2020-003280-26-GBImbria Pharmaceuticals, Inc.36
Completed
Not Applicable
Application observation regarding the dose change of the intrathecally required antispastic drug baclofen via a pump system and the occurrence of postoperative complications in the context of intrathecal baclofen therapy (ITB) in paraplegic patients at the BG Klinikum Hamburg in the period from 1991 to 2021.paralysis-related spasticity in para- & tetraplegicsDRKS00031760BG Klinikum Hamburg95
Active, not recruiting
Not Applicable
Pharmacodynamic and clinical evaluation of dose and taste-optimised low volume PEG-based bowel cleansing solutions using the split-dosing intake regimen in healthy subjects and in subjects undergoing screening colonoscopyBowel cleansing prior to colonoscopyMedDRA version: 14.1Level: PTClassification code 10066943Term: Bowel preparationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-003052-37-DEorgine Ltd